HealthcareServices

Vitreoretinal Disorder Market Trends and Insights: Global Forecast to 2030

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the vitreoretinal disorder market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Vitreoretinal Disorder Market covering 2026–2035?

The vitreoretinal disorder market size has demonstrated strong growth in recent years. It is anticipated to expand from $4.63 billion in 2025 to $4.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. This historical growth can be attributed to the rising prevalence of diabetic eye diseases, increased availability of optical coherence tomography, an uptick in ophthalmic surgical procedures, the expansion of specialty eye clinics, and enhanced diagnostic accuracy.

The vitreoretinal disorder market size is anticipated to undergo significant expansion in the next few years, set to grow to $6.71 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This projected growth throughout the forecast period stems from factors such as increasing demand for personalized retinal treatments, rising investments in ophthalmic innovation, the wider adoption of minimally invasive surgical techniques, the expanding utilization of AI-driven diagnostics, and a heightened focus on vision preservation therapies. Prominent trends for the forecast period include the increasing adoption of advanced retinal imaging techniques, a rise in minimally invasive vitreoretinal surgery, the growing integration of AI-based diagnostic tools, the expansion of targeted retinal therapies, and an enhanced emphasis on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23574&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Vitreoretinal Disorder Market?

An increasing occurrence of diabetic retinopathy is anticipated to drive expansion in the vitreoretinal disorder market. This eye condition develops when elevated blood sugar levels in individuals with diabetes cause harm to the blood vessels of the retina. The incidence of diabetic retinopathy is on the rise, primarily due to the growing prevalence of diabetes itself, which is often linked to sedentary lifestyles and inadequate blood sugar control, ultimately leading to damage in the retinal blood vessels. Managing vitreoretinal disorders is crucial for treating diabetic retinopathy, as it addresses complications such as vitreous hemorrhage and tractional retinal detachment, thereby preserving vision and preventing further retinal damage. For instance, in October 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that during 2022–23, 1.8% of screened First Nations people in Australia received treatment for diabetic retinopathy, reflecting a lower age-standardized treatment rate (1.3%) than non-Indigenous Australians (1.5%). Therefore, the growing incidence of diabetic retinopathy is consequently fueling the growth of the vitreoretinal disorder market.

What Segments Are Identified Within The Structure Of The Vitreoretinal Disorder Market?

The vitreoretinal disorder market covered in this report is segmented –

1) By Type: Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Other Types

2) By Diagnosis: Digital Fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Other Diagnosis

3) By Treatment: Surgery, Medication, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Retinal Tear: Atrophic Retinal Tear, Operculated Retinal Tear, Horseshoe Retinal Tear, Giant Retinal Tear

2) By Retinal Detachment: Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, Exudative Retinal Detachment

3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema

4) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration

5) By Macular Hole: Full-Thickness Macular Hole, Lamellar Macular Hole, Tractional Macular Hole

6) By Other Types: Epiretinal Membrane, Retinal Vein Occlusion, Retinal Artery Occlusion, Retinitis Pigmentosa, Uveitis, Vitreous Hemorrhage, Macular Edema, Central Serous Retinopathy, Proliferative Vitreoretinopathy

What Trends Are Expected To Impact The Competitive Landscape Of The Vitreoretinal Disorder Market?

Major companies within the vitreoretinal disorder market are prioritizing inventive offerings such as continuous delivery drug solutions to lessen injection frequency and improve patient outcomes. These continuous delivery drug solutions represent medical systems designed to provide a sustained, controlled release of medication directly to the eye, thereby diminishing the need for frequent injections, maintaining consistent therapeutic levels, and enhancing patient adherence and visual results. For example, in February 2025, Roche, a global pharmaceutical entity based in Switzerland, secured U.S. Food and Drug Administration (FDA) approval for its Susvimo (ranibizumab injection) 100 mg/mL, which is a Port Delivery System intended for diabetic macular edema (DME). Susvimo facilitates the continuous delivery of ranibizumab through a refillable implant, enabling patients to sustain their vision with merely two treatments per year, a considerable reduction compared to monthly eye injections. The system was put to the test in the Phase III Pagoda study, where it demonstrated persistent improvements in visual acuity and a safety profile consistent with previous approvals for neovascular age-related macular degeneration (nAMD). Susvimo’s innovative platform aims to reduce the burden of treatment, elevate patient convenience, and address the escalating global prevalence of DME.

Which Major Firms Are Strengthening Their Position In The Vitreoretinal Disorder Market?

Major companies operating in the vitreoretinal disorder market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Carl Zeiss Meditec AG, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Clearside Biomedical, Apellis Pharmaceuticals Inc., Genentech Inc., Oxurion NV, Adverum Biotechnologies Inc., Opthea Limited, Graybug Vision Inc., Kiora Pharmaceuticals Inc., Allegro Ophthalmics Inc., Lineage Cell Therapeutics Inc., Ocugen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/vitreoretinal-disorder-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Vitreoretinal Disorder Market?

North America was the largest region in the vitreoretinal disorder market in 2025. The regions covered in the vitreoretinal disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Vitreoretinal Disorder Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23574&type=smp

Browse Through More Reports Similar to the Global Vitreoretinal Disorder Market 2026, By The Business Research Company

Optic Nerve Disorders Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-nerve-disorders-treatment-global-market-report

Retinal Disorder Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Vitrectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/vitrectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795